News

EC fines pharma companies
Enlarge image

RegulatoryDenmarkEUGermanyUK

EC fines pharma companies

20.06.2013 - The European Commission has fined five pharma companies for delaying market entry of generic versions of the anti-depressant citalopram.

Danish drugmaker H.Lundbeck has to pay €93.8m, while the fine for German Merck KGaA/Generics is €21.4, its former subsidiary Generics UK pays €7.7m, while Arrow (now part of Zoetis), Alpharma (now part of Actavis), and Ranbaxy total € 52.2m in fines. According to investigations of the EC, in 2002, Lundbeck agreed with each of the generics makers to delay the market entry of cheaper versions of Lundbeck's branded citalopram, a blockbuster antidepressant.  

"It is unacceptable that a company pays off its competitors to stay out of its market and delay the entry of cheaper medicines“, stressed Commission Vice-President Joaquín Almunia. „Agreements of this type directly harm patients and national health systems, which are already under tight budgetary constraints. The Commission will not tolerate such anti-competitive practices".  “We are surprised and disappointed that the EC has reached this erroneous conclusion, which we totally disagree with, and it is therefore our intention to appeal,” stressed Lundbeck’s CEO Ulf Wiinberg. “It is wrong and extremely misleading to claim that these agreements have delayed the marketing of citalopram copies and thereby violated competition laws,” said Wiinberg. The agreements were meant to protect against patent infringements by the generic companies, he said.  Ranbaxy stated that the Commission misunderstood the facts. 

Citalopram was Lundbeck's best-selling product at the time. After Lundbeck's basic patent for the citalopram molecule had expired, it only held a number of related process patents which provided a more limited protection. Producers of cheaper, generic versions of citalopram therefore had the possibility to enter the market, which would have brought down the price for the medicine by approximately 90%.  According to the Commission, the generic producers agreed with Lundbeck in 2002 not to enter the market in return for substantial payments and other inducements from Lundbeck amounting to tens of millions of euros. 

Internal documents refer to a "club" being formed and "a pile of $$$" to be shared among the participants. Lundbeck paid significant lump sums, purchased generics' stock for the sole purpose of destroying it, and offered guaranteed profits in a distribution agreement. The agreements gave Lundbeck the certainty that the generics producers would stay out of the market for the duration of the agreements without giving the generic producers any guarantee of market entry thereafter. These agreements are very different from other settlements of patent disputes where generic companies are not simply paid off to stay out of the market.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/ec-fines-pharma-companies.html

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

BusinessSwitzerlandGermanyUK

28.10.2014 Swiss pharma company Novartis is selling its influenza vaccines business to Australian biopharma specialist CSL Ltd for US$275m.

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EPIGENOMICS4.34 EUR11.57%
  • PAION2.86 EUR10.85%
  • STRATEC BIOMEDICAL41.92 EUR3.92%

FLOP

  • CYTOS0.15 CHF-6.25%
  • MAGFORCE5.40 EUR-6.09%
  • CO.DON2.70 EUR-5.26%

TOP

  • BIOFRONTERA2.84 EUR29.1%
  • EPIGENOMICS4.34 EUR13.3%
  • VITA 344.42 EUR7.5%

FLOP

  • MAGFORCE5.40 EUR-21.7%
  • CYTOS0.15 CHF-16.7%
  • CO.DON2.70 EUR-14.0%

TOP

  • SANTHERA89.00 CHF2318.5%
  • CO.DON2.70 EUR172.7%
  • PAION2.86 EUR83.3%

FLOP

  • CYTOS0.15 CHF-96.2%
  • THERAMETRICS0.07 CHF-46.2%
  • 4SC0.94 EUR-43.4%

No liability assumed, Date: 30.10.2014